Innova Captab Limited (INNOVACAP) - Total Liabilities
Based on the latest financial reports, Innova Captab Limited (INNOVACAP) has total liabilities worth Rs7.47 Billion INR (≈ $80.74 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore INNOVACAP year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Innova Captab Limited - Total Liabilities Trend (2018–2026)
This chart illustrates how Innova Captab Limited's total liabilities have evolved over time, based on quarterly financial data. See Innova Captab Limited (INNOVACAP) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Innova Captab Limited Competitors by Total Liabilities
The table below lists competitors of Innova Captab Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ZheJiang RIFA Digital Precision Machinery Co Ltd
SHE:002520
|
China | CN¥1.54 Billion |
|
Shandong Astro-century Education&Technology Co Ltd
SHE:300654
|
China | CN¥254.31 Million |
|
Cracker Barrel Old Country Store
NASDAQ:CBRL
|
USA | $1.96 Billion |
|
HealthStream Inc
NASDAQ:HSTM
|
USA | $166.35 Million |
|
Ceepower Co Ltd
SHE:300062
|
China | CN¥1.18 Billion |
|
Shinry Technologies Co Ltd Class A
SHE:300745
|
China | CN¥2.21 Billion |
|
APAQ Technology Co Ltd
TW:6449
|
Taiwan | NT$4.06 Billion |
|
MK Restaurant Group Public Company Limited
BK:M
|
Thailand | ฿5.74 Billion |
Liability Composition Analysis (2018–2026)
This chart breaks down Innova Captab Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Innova Captab Limited (INNOVACAP) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.68 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Innova Captab Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Innova Captab Limited (2018–2026)
The table below shows the annual total liabilities of Innova Captab Limited from 2018 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | Rs7.47 Billion ≈ $80.74 Million |
+20.23% |
| 2025-03-31 | Rs6.21 Billion ≈ $67.16 Million |
+26.74% |
| 2024-03-31 | Rs4.90 Billion ≈ $52.99 Million |
-29.31% |
| 2023-03-31 | Rs6.93 Billion ≈ $74.96 Million |
+88.93% |
| 2022-03-31 | Rs3.67 Billion ≈ $39.68 Million |
+63.20% |
| 2021-03-31 | Rs2.25 Billion ≈ $24.31 Million |
+131359.06% |
| 2020-03-31 | Rs1.71 Million ≈ $18.49K |
-99.94% |
| 2019-03-31 | Rs2.98 Billion ≈ $32.23 Million |
+113.03% |
| 2018-03-31 | Rs1.40 Billion ≈ $15.13 Million |
-- |
About Innova Captab Limited
Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhib… Read more